Core Viewpoint - The company has submitted a filing to the China Securities Regulatory Commission (CSRC) for the full circulation of H-shares, aiming to convert a total of 68.0103 million domestic shares and unlisted foreign shares into H-shares for listing on the Hong Kong Stock Exchange [1] Group 1 - The company has applied to the CSRC for the conversion and listing of 68.0103 million shares [1] - The board of directors announced the receipt of a filing notice from the CSRC dated January 13, 2026, regarding the conversion and listing [1] - The CSRC filing for the conversion and listing has been completed, and if the company does not complete the process within 12 months from the notice date, an updated filing must be submitted [1] Group 2 - As of the date of the announcement, the details of the implementation plan for the full circulation of H-shares and the conversion and listing have not been finalized [1] - The company will provide further announcements regarding the progress of the H-share full circulation and conversion and listing in accordance with insider information regulations and/or listing rules [1]
友芝友生物-B：中国证监会就公司H股全流通发出备案通知